Results 191 to 200 of about 981,832 (295)

Implementing Ryan's Law on an Inpatient Medical Oncology Unit. [PDF]

Clin J Oncol Nurs
McKaig A, Varilla Ridad AR, Bell A, McParlane R, Quirch M.   +4 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Patients' education through scientifically-popular material [PDF]

Archive of Oncology, 2002
Jovanović Biljana, Brzaković Predrag, Jovićević-Bekić Ana, Mirković Verica, Živković Rada, Delić Jela   +5 more
doaj   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. [PDF]

Clin Transl Oncol
Pacheco-Barcia V, Obispo B, Tomas E, Salva de Torres C, Quintanar T, Paez D, Leon-Mateos L, Cancio H, Cortegoso A, Anido U, Quilez A, Tarazona N, Jimenez-Labaig P, Sanchez-Martinez DA, Sesma Goni A, Fernandez-Montes A, Felip E, Rodriguez C, Elez E.   +18 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. [PDF]

Clin Transl Oncol
Sánchez Cánovas M, López Robles J, García Verdejo FJ, Cacho Lavin D, Olivares H, Garrido Fernández A, Coma Salvans E, Quintanar Verduguez T, Salvador Coloma C, Fernández Garay D, Cumplido JD, Ferrer Pérez AI, Carbó Bagué A, Teigell Muñoz FJ, García López R, Martínez Marin A, Muñoz Martín AJ.   +16 more
europepmc   +1 more source

Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. [PDF]

Front Med (Lausanne)
Bongurala AR, Save D, Virmani A.
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Pharmacogenomics and Big Data in medical oncology: developments and challenges. [PDF]

Ther Adv Med Oncol
Marcu LG, Marcu DC.
europepmc   +1 more source